Last reviewed · How we verify

Bacillus Clausii Multi ATB Resist

Sanofi · FDA-approved active Small molecule

Bacillus clausii is a spore-forming probiotic bacterium that restores and maintains healthy gut microbiota, particularly in cases of antibiotic-associated dysbiosis.

Bacillus clausii is a spore-forming probiotic bacterium that restores and maintains healthy gut microbiota, particularly in cases of antibiotic-associated dysbiosis. Used for Prevention and treatment of antibiotic-associated diarrhea, Restoration of intestinal microbiota balance during antibiotic therapy.

At a glance

Generic nameBacillus Clausii Multi ATB Resist
SponsorSanofi
Drug classProbiotic
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

Bacillus clausii Multi ATB Resist contains spores of the bacterium Bacillus clausii, which colonizes the intestinal tract and produces metabolites that support normal gut flora recovery. The 'Multi ATB Resist' designation indicates this strain is resistant to multiple antibiotics, allowing it to survive and proliferate even during concurrent antibiotic therapy. By restoring microbial balance, it helps prevent antibiotic-associated diarrhea and other dysbiosis-related complications.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: